A practical reference on c-Met: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-27. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Savimbi used Jamba to augment UNITA's public image, investing heavily in local infrastructure. He opened the settlement to American and South African journalists, honed his public relations skills in frequent press conferences denouncing the MPLA, and lobbied for Western aid. Under the Reagan Doctrine, the US government opened covert channels to provide military assistance to UNITA. It repealed the Clark Amendment, which explicitly barred further CIA support for the UNITA and the FNLA, allowing the agency to resume Angolan operations. The Angolan government asserted this was "proof of the complicity there has always been between the US executive and the retrograde racist Pretoria regime" and it had "no alternative but to suspend the contacts it has had with US government envoys". In 1986, Savimbi visited Washington, where he met with American officials and was promised military hardware valued at about 10 million dollars, including FIM-92 Stinger surface-to-air missiles and BGM-71 TOW anti-tank missiles. The US also pledged to continue its support for UNITA even if it lost the umbrella of protection conferred by the SADF presence in southern Angola. At the US government's request, South Africa began lending UNITA a greater degree of material assistance, and aided the CIA in the acquisition of untraceable arms for the Angolan insurgents. The CIA was interested in acquiring Soviet and Eastern European arms for UNITA, as they could be easily passed off as weapons individual partisans had captured from FAPLA.
multiple cloning site (MCS) Also polylinker. A locus or sequence within a plasmid vector which contains multiple unique restriction sites recognized by various restriction endonucleases, which makes it possible for scientists to target the insertion of a DNA fragment (often a gene cassette) specifically to that locus and in the desired orientation, by digesting the insert and the vector with the same endonuclease(s) and then ligating them together via compatible restriction ends, a technique known as restriction cloning. Commercial plasmids designed for cloning commonly incorporate one or more multiple cloning sites.
It is a five-track album featuring two extended multi-chapter songs, "The Necromancer" and "The Fountain of Lamneth". Some critics said Caress of Steel was unfocused and an audacious move for the band because of the placement of two back-to-back protracted songs, as well as a heavier reliance on atmospherics and storytelling, a large deviation from Fly by Night. Intended to be their breakthrough album, Caress of Steel sold below expectations. The tour consisted of smaller venues and declining box office receipts, which led to it being nicknamed the Down the Tubes Tour.
Sources: en.wikipedia.org
=== Enzyme induction and inhibition === The duration and intensity of pharmacological action of most lipophilic drugs are determined by the rate they are metabolized to inactive products. The Cytochrome P450 monooxygenase system (CYP) is a crucial pathway in this regard. In general, anything that increases the rate of metabolism (e.g., enzyme induction) of a pharmacologically active metabolite will decrease the duration and intensity of the drug action. The opposite is also true, as in enzyme inhibition. However, in cases where an enzyme is responsible for metabolizing a pro-drug into a drug, enzyme induction can accelerate this conversion and increase drug levels, potentially causing toxicity. For example, chemotherapy prodrugs like cyclophosphamide (CPA) and ifosfamide (Ifex), which are initially inactive, become toxic as they are metabolized into cytotoxic compounds (such as phosphoramide mustard and chloroacetaldehyde) primarily from liver enzymes CYP2B6 and CYP3A4. Co-administration of a strong CYP inducer, such as phenytoin or rifampicin, accelerates metabolism and increases the rate of bioactivation which causes a higher concentration of cytotoxic metabolites that may lead to higher toxicity. This drug–drug interaction may enhance the risk of adverse effects, most notably severe myelosuppression and hemorrhagic cystitis.
{\displaystyle h=C{{\left[{\frac {k_{v}^{3}{{\rho }_{v}}g\left({{\rho }_{L}}-{{\rho }_{v}}\right)\left({{h}_{fg}}+0.4{{c}_{pv}}\left({{T}_{s}}-{{T}_{sat}}\right)\right)}{{{D}_{o}}{{\mu }_{v}}\left({{T}_{s}}-{{T}_{sat}}\right)}}\right]}^{{}^{1}\!\!\diagup \!\!{}_{4}\;}}}
Alyssa Burrows said the band's distinctive sound "came from Staley's vocal style and his lyrics dealing with personal struggles and addiction." Staley's songs were often considered "dark", with themes such as drug abuse, depression, and suicide, while Cantrell's lyrics often dealt with personal relationships.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.